All In Biotech

Free tool

FAERS Monitor: Fabrazyme

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 103979 or its brand name (Fabrazyme, Agalsidase Beta). Reports on generic versions are filed under their own applications.

Reports

9,357

Serious

4,797

51% of reports

Hospitalization

2,507

Death reported

703

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pyrexia526
  • pain514
  • malaise497
  • chills481
  • nausea477
  • fatigue433
  • dyspnoea428
  • headache382
  • vomiting378
  • weight decreased350
  • pain in extremity321
  • infusion related reaction301
  • dizziness290
  • weight increased287
  • condition aggravated275

Reports by year received

View as table
YearReports
2004259
2005312
2006197
2007169
2008181
2009170
2010187
2011193
2012175
2013313
2014782
2015590
2016473
2017588
2018508
2019468
2020331
2021480
2022630
2023642
2024619
2025575
2026515

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,802 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infusion related reactionSignal30110.29.22,500
chillsSignal4819.38.53,539
pyrexiaSignal5263.43.1912
weight increasedSignal2872.92.6354
weight decreasedSignal3502.82.5414
malaiseSignal4972.52.3476
pain in extremitySignal3212.52.2278
condition aggravatedSignal2752.01.8146
pain5141.91.7218
vomiting3781.81.6139
dyspnoea4281.71.5126
headache3821.41.239
nausea4771.41.246
dizziness2901.31.221
fatigue4331.31.122

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.